⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 2, 2024Frontiers in OncologyOpen Access

Predictive value of PD-L1 and TMB for short-term efficacy prognosis in non-small cell lung cancer and construction of prediction models

Shuling Shi Yingyi Wang Jingjing Wu Boya Zha Peihong Li Yukun Liu Yuchuan Yang Jinglin Kong Shibo Gao Haiyang Cui Linkuan Huangfu Xiaocong Sun Zhikai Li Tiansong Liang Yingjuan Zheng Daoke Yang

View Full Paper

Ask AI

Bookmark

Share

Abstract

To investigate the correlation between programmed death ligand 1(PD-L1), tumor mutation burden (TMB) and the short-term efficacy and clinical characteristics of anti-PD-1 immune checkpoint inhibitor combination chemotherapy in NSCLC patients. The efficacy of the prediction model was evaluated.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shi et al. (2024) studied this question.

synapsesocial.com/papers/68e6bd25b6db64358763d0e0 https://doi.org/10.3389/fonc.2024.1342262

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1High tumor mutational burden (TMB) and PD-L1 have similar predictive utility in 2L+ NSCLC patients (pts) treated with anti-PD-L1 and anti-CTLA-4Original Research · 2018 · 5 citations
2Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB Status2024 · 13 citations
3Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung CancerOriginal Research · 2019 · 72 citations
4Clinical value of tumor mutational burden for neoadjuvant and adjuvant immune checkpoint inhibitor in early-stage non-small cell lung cancerHuman Clinical Trial · 2026
5Variation of peripheral blood-based biomarkers for response of anti-PD-1 immunotherapy in non-small-cell lung cancer2024 · 9 citations

Plasma proteome-based test (PROphetNSCLC) predicts response to immune checkpoint inhibitors (ICI) independent of tumor programmed death-ligand 1(PD-L1) expression and tumor mutational burden (TMB)2024
Development and validation of a PD-L1 and tumor mutational burden-based predictive model for pathological complete response after neoadjuvant immunotherapy in resectable lung cancer2026
Unraveling the nexus: Tumor mutational burden, PD‐L1 expression, and oncogenic alterations in non–small cell lung cancer cytology specimens2026
Development and validation of a multiphase CT radiomics-based machine learning model for prognostic prediction in sarcomatoid renal cell carcinomaFrontiers in Oncology · 2026
Systemic immune-inflammation index predicts survival in gastric cancer: a systematic review and meta-analysisFrontiers in Oncology · 2026

More from Frontiers in Oncology

More from Zhengzhou University

More from First Affiliated Hospital of Zhengzhou University